Li Dexin

Dr. Li Dexin


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
GDGuofei Ding
Guofei Ding
QSQingyuan Shao
Qingyuan Shao
HYHaiyan Yu
Haiyan Yu
LJLiu Jiaqi
Liu Jiaqi
YLYingchao Li
Yingchao Li
YXYihong Xiao
Yihong Xiao
Tight junctions (TJs) are highly specialized membrane structural domains that hold cells together and form a continuous intercellular barrier in epithelial cells. TJs regulate paracellular permeability and participate in various cellular signaling pathways. As physical barriers, TJs can block viral entry into host cells; however, viruses use a variety of strategies to circumvent this barrier to facilitate their infection. This paper summarizes how viruses evade various barriers during infection by regulating the expression of TJs to facilitate their own entry into the organism causing infection, which will help to develop drugs targeting TJs to contain virus-related disease.

28 November 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LDLi Dexin
Li Dexin
QZQin Zhang
Qin Zhang
YLYutian Liu
Yutian Liu
MWMiaoli Wang
Miaoli Wang
LZLei Zhang
Lei Zhang
Yihong XiaoYihong Xiao
Yihong Xiao
African swine fever (ASF) caused by ASF virus (ASFV) is a fatal disease in pigs and results in great economic losses. Due to the lack of available vaccines and treatments, serological diagnosis of ASF plays a key role in the surveillance program, but due to the lack of knowledge and the complexity of the ASFV genome, the candidate target viral proteins are still being researched. False negativity is still a big obstacle during the diagnostic process. In this study, the high antigenic viral proteins p30, p54 and p72 were screened to find the antigenic dominant domains and the tandem His–p30–54–72 was derived. An indirect enzyme–linked immunosorbent assay (iELISA) coated with His–p30–54–72 was developed with a cut–off value of 0.371. A total of 192 clinical samples were detected by His–p30–54–72–coated indirect ELISA (iELISA) and commercial ASFV antibody kits. The results showed that the positive rate of His–p30–54–72–coated iELISA was increased by 4.7% and 14.6% compared with a single viral protein–based commercial ASFV antibody kits. These results provide a platform for future ASFV clinical diagnosis and vaccine immune effect evaluation.